SCHEMBL2936375

SCHEMBL2936375

CCOc1ccccc1CNC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
GAA P10253 2/20 0.59
ALOX15 P16050 2/20 0.59
USP2 O75604 1/20 0.59
PKM P14618 1/20 0.59
HSD17B10 Q99714 1/20 0.59
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 4/20 0.56
THRB P10828 2/20 0.55
CCNC P24863 1/20 0.55
CDK8 P49336 1/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
ATM Q13315 3/20 0.55
MAPT P10636 3/20 0.55
POLB P06746 2/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
PLEC Q15149 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8091198 0.87 ALDH1A1 (0.51) LMNAMEN1KMT2AGAAALOX15
SCHEMBL5724959 0.87 LMNA (0.59) LMNAMEN1KMT2AGAAALOX15
SCHEMBL5685631 0.86 HPGD (0.69) LMNAMEN1KMT2AGAAALOX15
SCHEMBL13702402 0.84 MEN1 (0.64) LMNAMEN1KMT2AGAAALOX15
SCHEMBL13702287 0.84 MEN1 (0.64) LMNAMEN1KMT2AGAAALOX15
SCHEMBL78148 0.83 ALDH1A1 (0.51) LMNAMEN1KMT2AGAAALOX15
SCHEMBL2938380 0.83 KMT2A (0.69) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL78090 0.83 CACNA1G (0.58) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL5305401 0.82 LMNA (0.60) LMNAMEN1KMT2AGAAKDM4E
SCHEMBL8479171 0.81 LMNA (0.54) LMNAMEN1KMT2AGAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD LMNA 2796/4885MEN1 1437/4885KMT2A 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.